Abstract:It is unclear whether relative abundance of EGFR mutations in plasma predicts tumor response treatment with EGFR–TKIs in advanced lung adenocarcinoma. The present prospective study enrolled patients with advanced lung adenocarcinoma in the first affiliated hospital of Wenzhou Medical University from 1 April 2016 to 1 January 2017. EGFR mutations detection in tumor tissues by ADx-ARMS and in plasma cfDNA by ADx-ARMS and ADx-SuperARMS were all tested. We enrolled patients with EGFR-mutant in tumor tissue and receiving EGFR-TKIs. Mutation-positive plasma by both methods carried high abundance of EGFR mutations. Plasma that was mutation positive by ADx-SuperARMS but the result by ADx-ARMS was negative harbored medium abundance. Mutation-negative plasma by both methods was recognized as low abundance group. The correlation between EGFR mutation abundance and clinical benefit from EGFR-TKIs treatment was analyzed using Kaplan-Meier curve, Chi-square test and Cox proportional hazards model. The study protocol was approved by the Institutional Review Board of the first affiliated hospital of Wenzhou Medical University(2016-017). 71 patients were enrolled, 42 harbored EGFR mutations in plasma detected by ADx-ARMS, while 53 were found positive result in plasma by ADx-SuperARMS. Median PFS was 10.0m and ORR was 64.8% in the patients with EGFR-mutant in tumor tissue. According to the results of the plasma detected by ADx-ARMS and ADx-SuperARMS, 42 were found high abundances of EGFR mutations, 11 were recognized as medium abundances group while the other 18 as low abundances. The ORRs were 69.0%，63.6% and 55.6% for patients with high, medium and low abundance of EGFR mutations, respectively. Pwith high abundances of EGFR mutations were seemed to acquire high ORRs, the difference was significant between high and low abundances group (P=0.006) but the differences were not significant when compared high abundances group with medium abundances group (P=0.732) and medium abundances group with low abundances group (P=0.114). Medium PFS for high, medium and low abundances groups were 11.0m, 8.5m and 9.0m, respectively(P<0.001). For the patients with 19-Del in tumor tissues, the ORRs were 70.4%，57.1% and 54.5% in high, medium and low abundance of EGFR mutations groups, respectively. Medium PFS of high abundance group was longer than medium and low abundance groups (12.0m vs 9.0m vs 9.0m). As for L858R, the ORRs were 66.7%，50.0% and 50.0%，respectively, Medium PFS were 9.6m, 5.5m and 9.5m. The relative EGFR mutation abundance in plasma could predict tumor response to EGFR-TKI treatment for advanced adenocarcinoma. The higher the EGFR mutation abundance is, the better efficacy of EGFR-TKI is.

EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

The Impact of EGFR Exon 19 Deletion Subtypes on Clinical Outcomes in Non-Small Cell Lung Cancer

Uncommon EGFR Mutations in a Cohort of Chinese NSCLC Patients and Outcomes of First-Line EGFR-TKIs and Platinum-Based Chemotherapy.

Relative Abundance of EGFR Mutations Predicts Benefit from Gefitinib Treatment for Advanced Non-Small-cell Lung Cancer.

Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer.

Different Stories for Different EGFR Exon 19 Deletion Variants

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21

Comparison of clinical outcome and efficacy of patients with advanced non-small cell lung cancer Harbouring different epidermal growth factor receptor mutations

Different Efficacy of EGFR Tyrosine Kinase Inhibitors and Prognosis in Patients with Subtypes of EGFR-mutated Advanced Non-Small Cell Lung Cancer: a Meta-Analysis.

Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients

Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.

P3.01-58 Relative Abundance of EGFR Mutations in Plasma Predicts Tumor Response to EGFR-TKI in Advanced Lung Adenocacarcinoma

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors

Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer

Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients Harboring Different Types of EGFR Mutations: A Retrospective Analysis